What's new — Hepatocellular carcinoma¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 0 |
| last 2 months | 0 |
| last 3 months | 0 |
| last 6 months | 2 |
| last year | 7 |
| older than a year | 318 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-05-01 | Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis — Gut ([PMID 42135055](https://pubmed.ncbi.nlm.nih.gov/42135055/){target="_blank" rel="noopener"}) | cirrhosis-and-risk-stratification, epidemiology-and-etiology, overview |
| 2026-05-01 | Second-line TKI after first-line immunotherapy-based treatment in advanced HCC: Reconstructed IPD meta-analysis — JHEP Rep ([PMID 42128139](https://pubmed.ncbi.nlm.nih.gov/42128139/){target="_blank" rel="noopener"}) | systemic-therapy |
| 2026-01-02 | Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma — J Hepatol ([PMID 41580093](https://pubmed.ncbi.nlm.nih.gov/41580093/){target="_blank" rel="noopener"}) | clinical-trials-landscape, surgical-resection-and-ablation |
| 2025-11-06 | Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study) — JHEP Rep ([PMID 41624484](https://pubmed.ncbi.nlm.nih.gov/41624484/){target="_blank" rel="noopener"}) | surveillance-and-early-detection |
| 2025-11-01 | Transarterial chemoembolization combined with immunotherapy and targeted therapy as first-line treatment for unresectable and non-metastatic hepatocellular carcinoma: a meta-analysis of phase III trials — Ther Adv Gastroenterol ([PMID 41268044](https://pubmed.ncbi.nlm.nih.gov/41268044/){target="_blank" rel="noopener"}) | locoregional-therapy |
| 2025-10-06 | HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort — J Hepatol ([PMID 41043723](https://pubmed.ncbi.nlm.nih.gov/41043723/){target="_blank" rel="noopener"}) | biomarkers |
| 2025-10-01 | Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis — JAMA Oncol ([PMID 40810932](https://pubmed.ncbi.nlm.nih.gov/40810932/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
Trials — what has moved¶
39 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 0 |
| trial records updated in the last month | 4 |
| trial records updated in the last 2 months | 8 |
| trial records updated in the last 3 months | 12 |
| trial records updated in the last 6 months | 17 |
| trial records updated in the last year | 24 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2023-11-18 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as | PHASE3 | 668 | Recurrence-Free Survival (RFS), as Determined by IRF | 124 | 470 | 58 |
| 2023-06-18 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patien | PHASE3 | 1324 | Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 4 | 435 | 1099 | 958 |
| 2021-11-05 | A Study of Atezolizumab in Combination With Bevacizumab Compared With | PHASE3 | 558 | Overall Survival (OS) in the Global Population | 288 | 642 | 477 |
| 2018-09-25 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and S | PHASE3 | 954 | Overall Survival (OS) | 358 | 938 | 817 |
| 2017-06-05 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular C | PHASE3 | 573 | Overall Survival (OS) | 286 | 528 | 500 |
| 2010-09-27 | A Phase III Study of Sorafenib in Patients With Advanced Hepatocellula | PHASE3 | 602 | Overall Survival (OS) | 719 | 1129 | 0 |
32 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| cirrhosis-and-risk-stratification | 2026-05-01 | 1 | 25 |
| epidemiology-and-etiology | 2026-05-01 | 1 | 25 |
| overview | 2026-05-01 | 1 | 36 |
| systemic-therapy | 2026-05-01 | 1 | 27 |
| clinical-trials-landscape | 2026-01-02 | 1 | 20 |
| surgical-resection-and-ablation | 2026-01-02 | 1 | 25 |
| surveillance-and-early-detection | 2025-11-06 | 1 | 27 |
| locoregional-therapy | 2025-11-01 | 1 | 25 |
| biomarkers | 2025-10-06 | 1 | 25 |
| patient-experience-and-advocacy | 2025-10-01 | 1 | 25 |
| liver-transplantation | 2025-09-02 | 0 | 26 |
| staging-and-treatment-allocation | 2025-09-02 | 0 | 25 |
| mash-masld-hcc | 2025-08-01 | 0 | 25 |
| guidelines | 2025-07-01 | 0 | 27 |
| red-flags-and-safety-concerns | 2025-06-06 | 0 | 25 |
| diagnosis-and-imaging | 2025-06-02 | 0 | 25 |
| molecular-landscape | 2024-07-02 | 0 | 26 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.